What You Should Know:
– A collaborative effort between COTA, PreciseDx, and Baptist Health South Florida seeks to revolutionize breast cancer recurrence risk assessment with the PreciseBreast™ (PDxBr) test. This AI-powered tool holds promise for faster, more accurate, and more affordable risk prediction compared to current methods.
– By utilizing AI technology, PreciseBreast™ has the potential to offer patients a faster, more accurate, and more affordable way to assess their risk of recurrence and make informed treatment decisions in collaboration with their physicians.
The Challenge of Breast Cancer Recurrence
One in eight women in the US will face a breast cancer diagnosis in their lifetime. Understanding a patient’s specific risk of recurrence is crucial for informing treatment decisions. While existing gene-expression tests offer some insights, they have limitations:
- Limited Accuracy: Current testing methods may not capture the full picture of recurrence risk.
- High Cost: Gene-expression tests can be expensive, potentially limiting access for some patients.
- Delayed Results: Waiting two to four weeks for test results can delay critical treatment decisions.
PreciseDx Aims to Transform Risk Assessment
PreciseDx’s PreciseBreast™ test utilizes artificial intelligence (AI) to analyze pathology slide images. This approach offers several potential advantages:
- Faster Results: PreciseDx delivers results in just 48 hours, accelerating the treatment planning process.
- Reduced Cost: At a significantly lower price point (80% reduction), the test could increase access to this vital information.
- Improved Accuracy: By leveraging AI, PreciseBreast™ may offer more precise risk assessment compared to traditional methods.
Validation Study Paves the Way
COTA and Baptist Health South Florida will be conducting a validation study to assess the effectiveness of PreciseBreast™. The study will compare the test’s results to traditional pathology reviews and existing gene-expression tests. If successful, Baptist Health South Florida will offer the test to its patients with IBC, potentially expanding access to this innovative technology.
Beyond Accuracy: The Benefits of AI-powered Testing
Beyond improved accuracy and faster turnaround time, the PreciseBreast™ test offers another significant advantage:
- Reduced Subjectivity: Traditional pathology reviews can be subjective. AI analysis, on the other hand, is designed to be objective and consistent, potentially leading to more reliable risk assessments.
“AI has allowed us to take a giant leap forward in the accuracy, affordability and accessibility of tools to better understand and treat breast cancer,” said Gerardo Fernandez, M.D., co-founder and chief scientific officer of PreciseDx. “Access to COTA’s best-in-class, real-world data that provides comprehensive insights into the cancer journeys of diverse patient populations will power more advanced and accurate AI learnings.”
